Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mylotarg in Nonmyeloablative Allogeneic Stem Cell Transplantation for High-Risk Leukemia and MDS
NCT00038805Phase 3Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2001
- Primary completion
- Nov 2004
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 1 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose of CMA-676. Started May 2001; status: terminated.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00038805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038805.